Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
RET mutation • RAS wild-type
|
Keytruda (pembrolizumab) • DF9001